Abstract: Objective To analyze the expression of CD133， secreted protein acidic and rich in cysteine（SPARC）， and AT rich interactive domain1A（ARID1A） in gastric cancer and their relationship with clinicopathological features and the prognosis of gastric cancer. Methods Expression of CD133， SPARC and ARID1A proteins were detected by immunohistochemistry （IHC）， and its correlation with clinicopathologic features and survival of gastric cancer was analyzed. Results The positive rates of CD133， SPARC and ARID1A was 26.7％（24／90）， 72.2％（65／90）and 30.0％ （27／90） in gastric cancer. The expression of CD133， SPARC and ARID1A was not related to sex， age and tumor size， but all related to TNM stage（P＜0.05）. The expression of ARID1A was also related to the depths of tumor invasion and tumor differentiation（P＜0.05）； the expression of CD133 was related to tumor differentiation， vascular invasion， lymph node metastasis and tumor position（P＜0.05）；the expression of SPARC was related to lymph node metastasis and vascular invasion（P＜0.05）. Cox analysis showed that TNM stage， chemotherapy after surgery， and the expression of ARID1A and SPARC were independent prognostic factors influencing disease free survival （DFS）； TNM stage， chemotherapy after surgery and the expression of CD133 were independent prognosis factors for overall survival （OS）. The median DFS and OS were 12 months and 17 months with positive expression of CD133， while in positive expression they were 41 months and 55 months with significance （P＜0.05）. The median DFS and OS with high SPARC expression levels was 41 and 54 months， higher than 10 months and 25 months in low expression （P＜0.05）. The median DFS and OS with positive ARID1A expression were not achieved， but higher than 20 months and 37months （P＜0.05）. Conclusion Detecting the expression of CD133， SPARC， and ARID1A contributes to the prediction of the prognosis of gastric cancer and selection of adjuvant chemotherapy for priority patients， and provides evidence for the therapy of gastric cancer.